Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Hypersensitivity Reaction

  Free Subscription

Articles published in Br J Dermatol

Retrieve available abstracts of 129 articles:
HTML format

Single Articles

    June 2022
  1. BETTUZZI T, Hua C, Diaz E, Colin A, et al
    Epidermal necrolysis: characterization of different phenotypes using an unsupervised clustering analysis.
    Br J Dermatol. 2022;186:1037-1039.

    May 2022
  2. CHEN CW, Wei JC
    Response to 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes'.
    Br J Dermatol. 2022;186:910-911.

  3. GOLDENBERG M, Krishna SG, Milani-Nejad N, Trinidad JC, et al
    Response to: 'Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9(th) and 10(th) Revision codes': reply from the authors.
    Br J Dermatol. 2022;186:911.

    April 2022
  4. BIEBER T, Reich K, Paul C, Tsunemi Y, et al
    Efficacy and Safety of Baricitinib in Combination With Topical Corticosteroids in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response, Intolerance, or Contraindication to Cyclosporine: Results From a Randomized, Placebo-Control
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21630.
    PubMed     Abstract available

  5. LAQUER V, Parra V, Lacour JP, Takahashi H, et al
    IL-33 antibody failed to demonstrate benefit in a phase 2 double-blind, randomised placebo-controlled study in adult patients with moderate-to-severe atopic dermatitis.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21631.

  6. JENDOUBI F, Shourik J, Seneschal J, Giordano-Labadie F, et al
    Longer Dupilumab Dosing Intervals in Adult Patients with Atopic Dermatitis: Experience from a French Multicentre Retrospective Cohort Study.
    Br J Dermatol. 2022 Apr 28. doi: 10.1111/bjd.21628.

  7. SIMPSON EL, Bissonnette R, Paller AS, King B, et al
    The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): A Clinical Outcome Measure for the Severity of Atopic Dermatitis.
    Br J Dermatol. 2022 Apr 20. doi: 10.1111/bjd.21615.
    PubMed     Abstract available

  8. Revolutionizing Atopic Dermatitis, 11-13 December 2021.
    Br J Dermatol. 2022;186:e135-e185.

    Targeting the itch-scratch vicious circle in atopic eczema.
    Br J Dermatol. 2022;186:608.

    March 2022
  10. JACOBY TV, Otto TS, Asdourian MS, Shah N, et al
    Association of preexisting drug allergies with cutaneous immune related adverse events among patients on immune checkpoint inhibitor therapy.
    Br J Dermatol. 2022 Mar 15. doi: 10.1111/bjd.21243.

  11. NOVAK N, Cabanillas B
    Herpesvirus, serious and opportunistic infections associated with atopic dermatitis.
    Br J Dermatol. 2022 Mar 6. doi: 10.1111/bjd.20982.

  12. SABROE RA, Lawlor F, Grattan CEH, Ardern-Jones MR, et al
    British Association of Dermatologists guidelines for the management of people with chronic urticaria 2021.
    Br J Dermatol. 2022;186:398-413.

  13. GOLDENBERG M, Amigo M, Krishna SG, Milani-Nejad N, et al
    Validation of generalized drug-related rash diagnoses using International Classification of Diseases 9th and 10th Revision codes.
    Br J Dermatol. 2022;186:583-585.

    February 2022
  14. NGUYEN R
    Ocular conjunctivitis in biological therapies for atopic dermatitis.
    Br J Dermatol. 2022 Feb 16. doi: 10.1111/bjd.20945.

    Easy assessment tool for disease severity of atopic dermatitis in clinical practice.
    Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20951.

    Atopic dermatitis: filaggrin and skin barrier dysfunction.
    Br J Dermatol. 2022 Feb 6. doi: 10.1111/bjd.20946.

  17. GLEESON D, Cliff S, Das M
    Eruptive keratoacanthomas associated with dupilumab therapy.
    Br J Dermatol. 2022;186:376-377.
    PubMed     Abstract available

  18. GAUDIN O, Milpied B, Papouin B, Hue S, et al
    Lupus erythematosus and epidermal necrolysis: a case series of 16 patients.
    Br J Dermatol. 2022;186:372-374.

    January 2022
  19. PAKHCHANIAN H, Raiker R, Wolf M, Trotter SC, et al
    Examining the Risk of Breakthrough Infection and COVID-19 Vaccination Safety in Atopic Dermatitis Patients.
    Br J Dermatol. 2022 Jan 27. doi: 10.1111/bjd.21038.

  20. YOSIPOVITCH G, Papp K, Forman S, Han G, et al
    The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase 3 trials.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21015.

  21. KOZERA E, Stewart T, Gill K, De La Vega MA, et al
    Dupilumab Associated Head and Neck Dermatitis is Associated with Elevated Pre-Treatment Serum Malassezia-Specific Immunoglobulin E: A Multicenter, Prospective Cohort Study.
    Br J Dermatol. 2022 Jan 18. doi: 10.1111/bjd.21019.

  22. KEZIC S, McAleer MA, Jakasa I, Goorden SMI, et al
    Children with atopic dermatitis show increased activity of beta- glucocerebrosidase and stratum corneum levels of glucosylcholesterol that are strongly related to local cytokine milieu.
    Br J Dermatol. 2022 Jan 7. doi: 10.1111/bjd.20979.
    PubMed     Abstract available

  23. ARENTS BWM, Zuuren EJV, Vermeulen S, Schoones JW, et al
    Global Guidelines in Dermatology Mapping Project (GUIDEMAP) - a systematic review of atopic dermatitis clinical practice guidelines: are they clear, unbiased, trustworthy and evidence based (CUTE)?
    Br J Dermatol. 2022 Jan 4. doi: 10.1111/bjd.20972.
    PubMed     Abstract available

    November 2021
  24. SINIKUMPU SP, Huilaja L
    Challenges of multidimensional atopic dermatitis.
    Br J Dermatol. 2021 Nov 24. doi: 10.1111/bjd.20874.

  25. DEZOTEUX F, El Mesbahi S, Tedbirt B, Grosjean J, et al
    Immunomodulatory or/and immunosuppressive drugs should not avoid skin test for the assessment of drug allergy.
    Br J Dermatol. 2021 Nov 22. doi: 10.1111/bjd.20901.
    PubMed     Abstract available

  26. MARNIQUET ME, Seneschal J, Darrigade AS, Staumont-Salle D, et al
    Reasons for Discontinuation of dupilumab in Adult Atopic Dermatitis in Clinical Practice.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20883.
    PubMed     Abstract available

  27. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Risk of herpesvirus, serious, and opportunistic infections in atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2021 Nov 8. doi: 10.1111/bjd.20887.
    PubMed     Abstract available

  28. CHIESA Z
    How important is it to distinguish between eczema and atopic dermatitis in infants? Implications for prognosis and epidemiological research.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20814.

  29. BEN ABDALLAH H, Vestergaard C
    Atopic dermatitis, hypertension and cardiovascular disease.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20802.

  30. PALLER AS, Tan JKL, Bagel J, Rossi AB, et al
    IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20872.
    PubMed     Abstract available

  31. KABASHIMA K, Matsumura T, Komazaki H, Kawashima M, et al
    Nemolizumab plus topical agents in patients with atopic dermatitis and moderate-to-severe pruritus provide improvement in pruritus and signs of atopic dermatitis for up to 68 weeks: results from two phase III, long-term studies.
    Br J Dermatol. 2021 Nov 2. doi: 10.1111/bjd.20873.
    PubMed     Abstract available

    October 2021
  32. HOYER A, Rehbinder EM, Fardig M, Asad S, et al
    Filaggrin mutations in relation to skin barrier and atopic dermatitis in early infancy.
    Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20831.
    PubMed     Abstract available

  33. GUTERMUTH J, Pink AE, Worm M, Soldbro L, et al
    Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of cyclosporine A: a placebo-controlled, randomized, Phase 3 clinical trial (ECZTRA 7).
    Br J Dermatol. 2021 Oct 26. doi: 10.1111/bjd.20832.
    PubMed     Abstract available

  34. WOLLENBERG A, Beck LA, de Bruin Weller M, Simpson EL, et al
    Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.
    Br J Dermatol. 2021 Oct 12. doi: 10.1111/bjd.20810.
    PubMed     Abstract available

  35. PUELLES J, Fofana F, Rodriguez D, Silverberg JI, et al
    Psychometric Validation and Responder Definition of Sleep Disturbance Numerical Rating Scale in Moderate-To-Severe Atopic Dermatitis.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20783.
    PubMed     Abstract available

  36. BERMINGHAM WH, Ardern-Jones MR, Huissoon AP, Krishna MT, et al
    Forewarned is forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-CoV-2 vaccine uptake and global public health.
    Br J Dermatol. 2021;185:838-839.

    September 2021
  37. NAKAMURA T, Haider S, Fontanella S, Murray CS, et al
    Modelling trajectories of parentally reported and physician-confirmed atopic dermatitis in a birth cohort study.
    Br J Dermatol. 2021 Sep 26. doi: 10.1111/bjd.20767.
    PubMed     Abstract available

  38. ULRIKSDOTTER J, Svedman C, Bruze M, Mowitz M, et al
    Allergic contact dermatitis caused by dipropylene glycol diacrylate in the Omnipod(R) insulin pump.
    Br J Dermatol. 2021 Sep 12. doi: 10.1111/bjd.20751.
    PubMed     Abstract available

  39. DING J, Joseph M, Yau N, Khosa F, et al
    Underreporting of race and ethnicity in pediatric atopic dermatitis clinical trials: A cross-sectional analysis of demographic reporting and representation.
    Br J Dermatol. 2021 Sep 4. doi: 10.1111/bjd.20740.
    PubMed     Abstract available

  40. FORSYTH JR, Russell E, McPherson T
    A retrospective case series of paediatric Stevens-Johnson syndrome and toxic epidermal necrolysis: evaluation of practice using the British Association of Dermatology's National Guidelines for children and young people.
    Br J Dermatol. 2021 Sep 4. doi: 10.1111/bjd.20741.
    PubMed     Abstract available

  41. HACARD F, Giraudeau B, d'Acremont G, Jegou MH, et al
    Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the Centre of Evidence of the French Society of Dermatology.
    Br J Dermatol. 2021;185:658-660.

    August 2021
  42. FLORES C
    Decoding the pharmacogenetics of nonsteroidal anti-inflammatory drug hypersensitivity.
    Br J Dermatol. 2021 Aug 30. doi: 10.1111/bjd.20693.

  43. BORTOLUZZI P, Ferrucci S, Galimberti D, Garavelli F, et al
    New insights on ocular surface disease in atopic dermatitis patients treated with dupilumab.
    Br J Dermatol. 2021 Aug 25. doi: 10.1111/bjd.20706.
    PubMed     Abstract available

  44. STANDL M
    Addressing the causality of the association of atopic dermatitis with depression and anxiety using Mendelian randomization.
    Br J Dermatol. 2021 Aug 17. doi: 10.1111/bjd.20622.

  45. JACOBY TV, Chang MS, Thompson LL, Foreman RK, et al
    Histopathologically-confirmed lichenoid eruptions from immune checkpoint inhibitor therapy: A retrospective cohort analysis.
    Br J Dermatol. 2021 Aug 10. doi: 10.1111/bjd.20698.
    PubMed     Abstract available

  46. ZHAO Y, Wu L, Lu Q, Gao X, et al
    The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study.
    Br J Dermatol. 2021 Aug 6. doi: 10.1111/bjd.20690.
    PubMed     Abstract available

  47. CHRETIEN B, Dolladille C, Alexandre J, Fedrizzi S, et al
    Dupilumab-associated arthralgia: an observational retrospective study in VigiBase((R)).
    Br J Dermatol. 2021;185:464-465.

  48. SHAO SC, Kuo LT, Lai EC, Chi CC, et al
    Oral corticosteroid bursts and severe adverse events: a critical appraisal.
    Br J Dermatol. 2021;185:313-314.

    July 2021
  49. YOUSAF M, Ayasse M, Ahmed A, Gwillim E, et al
    Association between Atopic Dermatitis and Hypertension: A Systematic Review and Meta-Analysis.
    Br J Dermatol. 2021 Jul 28. doi: 10.1111/bjd.20661.
    PubMed     Abstract available

  50. SAEKI H, Baba N, Ito K, Yokota D, et al
    Difamilast ointment, a selective phosphodiesterase 4 inhibitor, in paediatric patients with atopic dermatitis: A phase 3 randomised double-blind, vehicle-controlled trial.
    Br J Dermatol. 2021 Jul 21. doi: 10.1111/bjd.20655.
    PubMed     Abstract available

  51. PROCOPIO-AZEVEDO AC, Rabello VBS, Muniz MM, Figueiredo-Carvalho MHG, et al
    Hypersensitivity reactions in sporotrichosis: A retrospective cohort of 325 patients from a reference hospital in Rio de Janeiro, Brazil (2005-2018).
    Br J Dermatol. 2021 Jul 14. doi: 10.1111/bjd.20646.
    PubMed     Abstract available

  52. CHEN CB, Chung WH
    Current agreement on the management of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Br J Dermatol. 2021 Jul 5. doi: 10.1111/bjd.20515.

  53. MURRELL DF, Paul CF
    What instruments should we add to our toolbox for measuring the severity and control of eczema?
    Br J Dermatol. 2021;185:13-14.

  54. SORIANO LF, Chowdhury MMU, Cooper SM, Cousen P, et al
    Current prevalence and relevance of positive patch test reactions to cosmetic and noncosmetic isothiazolinones in the UK.
    Br J Dermatol. 2021;185:223-225.

  55. THOMAS KS, Apfelbacher CA, Chalmers JR, Simpson E, et al
    Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting.
    Br J Dermatol. 2021;185:139-146.
    PubMed     Abstract available

  56. HUGHES AJ, Tawfik SS, Baruah KP, O'Toole EA, et al
    Tape strips in dermatology research.
    Br J Dermatol. 2021;185:26-35.
    PubMed     Abstract available

    June 2021
  57. BRODERICK C, Christian N, Apfelbacher C, Bosma AL, et al
    The BIOMarkers in Atopic Dermatitis and Psoriasis (BIOMAP) Glossary: developing a lingua franca to facilitate data harmonisation and cross-cohort analyses.
    Br J Dermatol. 2021 Jun 16. doi: 10.1111/bjd.20587.
    PubMed     Abstract available

    Association of atopic dermatitis and autoimmune comorbidities: is it real?
    Br J Dermatol. 2021 Jun 14. doi: 10.1111/bjd.20497.

    Psychiatric conditions in children with atopic dermatitis.
    Br J Dermatol. 2021 Jun 11. doi: 10.1111/bjd.20394.

  60. LINDER M
    Using epidemiological methods to quantify the risk of serious infections in children with atopic dermatitis.
    Br J Dermatol. 2021 Jun 11. doi: 10.1111/bjd.20395.

  61. WELSH E, Cardenas-de la Garza JA, Cuellar-Barboza A, Franco-Marquez R, et al
    SARS-CoV-2 spike protein positivity in pityriasis rosea-like and urticaria-like rashes of COVID-19.
    Br J Dermatol. 2021;184:1194-1195.

    May 2021
  62. TAIEB A, Katoh N
    Regional differences between Japan and the Netherlands in atopic dermatitis patient-reported outcome measures: which interpretation?
    Br J Dermatol. 2021 May 31. doi: 10.1111/bjd.20424.

    How clinical phenotypes can translate into taxonomy: can we judge atopic dermatitis by its cover?
    Br J Dermatol. 2021 May 31. doi: 10.1111/bjd.20434.

  64. JURADO-ESCOBAR R, Dona I, Perkins JR, Laguna JJ, et al
    Polymorphisms in eicosanoid-related biosynthesis enzymes associated with acute urticaria/angioedema induced by nonsteroidal anti-inflammatory drug hypersensitivity.
    Br J Dermatol. 2021 May 6. doi: 10.1111/bjd.20440.
    PubMed     Abstract available

  65. NGUYEN C, Yale K, Casale F, Ghigi A, et al
    SARS-CoV-2 infection in patients with atopic dermatitis: a cross-sectional study.
    Br J Dermatol. 2021 May 6. doi: 10.1111/bjd.20435.
    PubMed     Abstract available

    Hand eczema in young people: atopic dermatitis and beyond.
    Br J Dermatol. 2021 May 4. doi: 10.1111/bjd.20142.

  67. BHANOT A, Peters TJ, Ridd MJ
    Assessing the validity, responsiveness and reliability of the Recap measure of eczema control.
    Br J Dermatol. 2021;184:955-957.

    Long-term safety of dupilumab in children.
    Br J Dermatol. 2021;184:792-793.

  69. ASCOTT A, Mansfield KE, Schonmann Y, Mulick A, et al
    Atopic eczema and obesity: a population-based study.
    Br J Dermatol. 2021;184:871-879.
    PubMed     Abstract available

    April 2021
  70. CHAN WH, Srivastava R, Damaraju N, Do H, et al
    Automated detection of skin reactions in epicutaneous patch testing using machine learning.
    Br J Dermatol. 2021 Apr 7. doi: 10.1111/bjd.20141.
    PubMed     Abstract available

  71. BAURECHT H, Welker C, Baumeister SE, Weidnger S, et al
    Relationship between Atopic Dermatitis, Depression and Anxiety: a two-sample Mendelian randomization study.
    Br J Dermatol. 2021 Apr 4. doi: 10.1111/bjd.20092.
    PubMed     Abstract available

  72. JENDOUBI F, Shourick J, Negretto M, Laurent C, et al
    Cutaneous mastocytosis in adult patients with serum tryptase level under 20 ng/ml: why we should investigate further.
    Br J Dermatol. 2021 Apr 3. doi: 10.1111/bjd.20098.
    PubMed     Abstract available

    March 2021
  73. SILVERBERG JI, Lai JS, Cella D
    Reliability and meaningful change of the Patient-Reported Outcomes Measurement Information System Itch Questionnaire(R) (PIQ) Item-Banks in adults with atopic dermatitis.
    Br J Dermatol. 2021 Mar 18. doi: 10.1111/bjd.20066.
    PubMed     Abstract available

  74. MIRZA FN, Wang A, Ramachandran SM, Damsky W, et al
    Dupilumab induced phenotype switch from atopic dermatitis to psoriasis is characterized by de novo IL-17A expression: a case report.
    Br J Dermatol. 2021 Mar 17. doi: 10.1111/bjd.20064.
    PubMed     Abstract available

  75. YIU ZZN, Harding G, Griffiths CEM, Warren RB, et al
    Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single centre, cross-sectional study.
    Br J Dermatol. 2021 Mar 17. doi: 10.1111/bjd.20062.
    PubMed     Abstract available

  76. SCHONMANN Y, Mansfield KE, Mulick A, Roberts A, et al
    Inflammatory Skin Diseases and the Risk of Chronic Kidney Disease - Population-Based Case-control and Cohort analyses.
    Br J Dermatol. 2021 Mar 17. doi: 10.1111/bjd.20067.
    PubMed     Abstract available

  77. DE WIJS LEM, Fujimoto RFT, Andrinopoulou ER, Nijsten TEC, et al
    Dupilumab treatment in atopic dermatitis patients in the Netherlands versus Japan: a comparative cohort study revealing a discrepancy in patient-reported outcome measures.
    Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19897.
    PubMed     Abstract available

  78. BRUGGEN MC, Le ST, Walsh S, Toussi A, et al
    Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus.
    Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19893.
    PubMed     Abstract available

  79. MULICK AR, Mansfield KE, Silverwood RJ, Buddu-Aggrey A, et al
    Four childhood atopic dermatitis subtypes identified from trajectory and severity of disease and internally validated in a large UK birth cohort.
    Br J Dermatol. 2021 Mar 2. doi: 10.1111/bjd.19885.
    PubMed     Abstract available

    February 2021
    The importance of keratinocyte-dendritic cell interactions in understanding fragrance allergy.
    Br J Dermatol. 2021 Feb 18. doi: 10.1111/bjd.19828.

  81. ABUABARA K, Nicholls SG, Langan SM, Guttman-Yassky E, et al
    Priority research questions in atopic dermatitis: An International Eczema Council eDelphi consensus.
    Br J Dermatol. 2021 Feb 11. doi: 10.1111/bjd.19874.
    PubMed     Abstract available

  82. NAPOLITANO M, Caiazzo G, Fabbrocini G, Balato A, et al
    Increased expression of interleukin-23A in lesional skin of patients with atopic dermatitis with psoriasiform reaction during dupilumab treatment.
    Br J Dermatol. 2021;184:341-343.

  83. LUCAS JA
    Using electronic health records to examine links between atopic dermatitis and obesity.
    Br J Dermatol. 2021 Feb 1. doi: 10.1111/bjd.19758.

  84. GONCALO M, Gimenez-Arnau A, Al-Ahmad M, Ben-Shoshan M, et al
    The global burden of chronic urticaria for the patient and society.
    Br J Dermatol. 2021;184:226-236.
    PubMed     Abstract available

    January 2021
  85. ENDRE KMA, Landro L, LeBlanc M, Gjersvik P, et al
    Diagnosing Atopic Dermatitis in Infancy Using Established Diagnostic Criteria: A Cohort Study.
    Br J Dermatol. 2021 Jan 28. doi: 10.1111/bjd.19831.
    PubMed     Abstract available

  86. DROITCOURT C, Vittrup I, Dupuy A, Egeberg A, et al
    The risk of systemic infections requiring hospitalisation in children with atopic dermatitis: a Danish retrospective nationwide cohort study.
    Br J Dermatol. 2021 Jan 21. doi: 10.1111/bjd.19825.
    PubMed     Abstract available

  87. VITTRUP I, Andersen YMF, Droitcourt C, Skov L, et al
    Association between hospital-diagnosed atopic dermatitis and psychiatric disorders and medication use in childhood.
    Br J Dermatol. 2021 Jan 16. doi: 10.1111/bjd.19817.
    PubMed     Abstract available

  88. SILVERBERG JI, Warshaw EM, Maibach HI, DeKoven JG, et al
    Hand Eczema in Children Referred for Patch Testing: North American Contact Dermatitis Group Data, 2000-2016.
    Br J Dermatol. 2021 Jan 16. doi: 10.1111/bjd.19818.
    PubMed     Abstract available

  89. KAMIDO H, Shimomiya D, Kogame T, Takimoto-Ito R, et al
    Inducible skin-associated lymphoid tissue (iSALT) in a patient with Schnitzler syndrome who manifested wheals on recurrent localized erythema.
    Br J Dermatol. 2021 Jan 14. doi: 10.1111/bjd.19808.
    PubMed     Abstract available

  90. Revolutionizing Atopic Dermatitis, 13-14 December 2020.
    Br J Dermatol. 2021 Jan 11. doi: 10.1111/bjd.19722.

  91. EXPOSITO-SERRANO V, Curto-Barredo L, Aguilera Peiro P, Gomez Armayones S, et al
    Omalizumab for the treatment of chronic inducible urticaria in 80 patients.
    Br J Dermatol. 2021;184:167-168.

    What should be in the facial patch testing series for 2020?
    Br J Dermatol. 2021;184:13.

    December 2020
  93. MORRA DE, Drucker AM
    Tralokinumab for atopic dermatitis: a promising new therapy.
    Br J Dermatol. 2020 Dec 21. doi: 10.1111/bjd.19699.

  94. MCALEER MA, Jakasa I, Stefanovic N, McLean WHI, et al
    Topical Corticosteroids Normalize both Skin and Systemic Inflammatory Markers in Infant Atopic Dermatitis.
    Br J Dermatol. 2020 Dec 2. doi: 10.1111/bjd.19703.
    PubMed     Abstract available

  95. PAN CX, Jee YH, Moore KJ, Kraft P, et al
    Relationship Between Body Mass Index and Atopic Dermatitis: Critical Appraisal of a Mendelian Randomization Approach in Exploring Causality.
    Br J Dermatol. 2020 Dec 1. doi: 10.1111/bjd.19702.
    PubMed     Abstract available

    November 2020
  96. LICHTER J, Silva E Sousa M, Peter N, Sahli F, et al
    Skin sensitisation to fragrance hydroperoxides: interplay between dendritic cells, keratinocytes and free radicals.
    Br J Dermatol. 2020 Nov 18. doi: 10.1111/bjd.19685.
    PubMed     Abstract available

  97. MIYANO T, Tanaka RJ
    Identification of keratinocyte subpopulations in transcriptome to evaluate drug effects in atopic dermatitis.
    Br J Dermatol. 2020 Nov 8. doi: 10.1111/bjd.19615.

  98. VAZQUEZ T, Concha JSS, Werth VP
    Patient-oriented outcomes for atopic dermatitis.
    Br J Dermatol. 2020 Nov 8. doi: 10.1111/bjd.19614.

  99. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS((R)) ) Itch Questionnaire: itch severity assessments in adults with atopic dermatitis.
    Br J Dermatol. 2020;183:e149-e170.
    PubMed     Abstract available

  100. WANG HL, Sun J, Qian ZM, Gong YQ, et al
    Association between Air Pollution and Atopic Dermatitis in Guangzhou, China: Modification by Age and Season.
    Br J Dermatol. 2020 Nov 1. doi: 10.1111/bjd.19645.
    PubMed     Abstract available

    The value of ongoing surveillance on the prevalence of contact sensitization.
    Br J Dermatol. 2020;183:800-801.

  102. BELLON T, Kardaun SH
    CXCL10/IP-10, an early biomarker for late sequelae in DRESS?
    Br J Dermatol. 2020;183:804-805.

    October 2020
  103. SEARS AV, Woolf RT, Gribaleva E, Abdelrahman W, et al
    Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: A single centre, prospective one-year observational cohort study of the first 100 patients treated.
    Br J Dermatol. 2020 Oct 27. doi: 10.1111/bjd.19631.
    PubMed     Abstract available

  104. IVERT LU, Wahlgren CF, Lindelof B, Dal H, et al
    Association between atopic dermatitis and autoimmune diseases: a population-based case-control study.
    Br J Dermatol. 2020 Oct 22. doi: 10.1111/bjd.19624.
    PubMed     Abstract available

  105. SORIANO LF, Bertram CG, Chowdhury MMU, Cousen P, et al
    Prevalence of allergic contact dermatitis to decyl and lauryl glucoside in the UK and Ireland.
    Br J Dermatol. 2020 Oct 14. doi: 10.1111/bjd.19603.
    PubMed     Abstract available

  106. LAUGHTER MR, Maymone MBC, Mashayekhi S, Arents BWM, et al
    The global burden of atopic dermatitis: lessons from the GBD Study - 1990 to 2017.
    Br J Dermatol. 2020 Oct 2. doi: 10.1111/bjd.19580.
    PubMed     Abstract available

    September 2020
  107. SILVERBERG JI, Toth D, Bieber T, Alexis AF, et al
    Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial.
    Br J Dermatol. 2020 Sep 30. doi: 10.1111/bjd.19573.
    PubMed     Abstract available

  108. WOLLENBERG A, Blauvelt A, Guttman-Yassky E, Worm M, et al
    Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
    Br J Dermatol. 2020 Sep 30. doi: 10.1111/bjd.19574.
    PubMed     Abstract available

  109. NETTIS E, Fabbrocini G, Ortoncelli M, Pellacani G, et al
    Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients.
    Br J Dermatol. 2020 Sep 30. doi: 10.1111/bjd.19577.
    PubMed     Abstract available

  110. CORK MJ, Thaci D, Eichenfield LF, Arkwright PD, et al
    Dupilumab provides favourable long-term safety and efficacy in children aged >/= 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open-label phase IIa study and subsequent phase III open-label extension study.
    Br J Dermatol. 2020 Sep 24. doi: 10.1111/bjd.19460.
    PubMed     Abstract available

  111. POLAK ME
    Early life regulation of inflammation in atopic dermatitis by microRNA.
    Br J Dermatol. 2020 Sep 20. doi: 10.1111/bjd.19475.

  112. PATTINSON R, Bundy C
    Self-management: PROMs can prompt support.
    Br J Dermatol. 2020;183:418-419.

    August 2020
  113. SILVERBERG JI, Lei D, Yousaf M, Janmohamed SR, et al
    What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.
    Br J Dermatol. 2020 Aug 5. doi: 10.1111/bjd.19457.
    PubMed     Abstract available

  114. RUSSELL E, Walker S, McPherson T
    Diagnosis of Mycoplasma aetiology in Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis.
    Br J Dermatol. 2020 Aug 5. doi: 10.1111/bjd.19458.
    PubMed     Abstract available

  115. ARENTS BWM, Leonardi-Bee J
    Eczema and water hardness: another piece of the puzzle found?
    Br J Dermatol. 2020;183:203-204.

    May 2020
  116. WALBURN J, Sarkany RPE
    Quality of life in the photodermatoses: the hidden toll of photosensitivity.
    Br J Dermatol. 2020;182:1077.

  117. ARDELEANU M, Shumel B, Rossi AB, Graham NMH, et al
    Response to R. Waldman et al.: 'Does IL-4 inhibition play a role in dupilumab-associated conjunctivitis?'
    Br J Dermatol. 2020;182:1310-1312.

    April 2020
  118. ZOMORODI N, Butt M, Maczuga S, Marks J, et al
    Cost and Diagnostic Characteristics of Toxicodendron Dermatitis in the United States: A retrospective cross-sectional analysis.
    Br J Dermatol. 2020 Apr 15. doi: 10.1111/bjd.19130.
    PubMed     Abstract available

  119. BASU P, Tong Y, Hinds BR, Schneider JA, et al
    Nivolumab-induced toxic epidermal necrolysis with retiform purpura.
    Br J Dermatol. 2020 Apr 13. doi: 10.1111/bjd.19031.

    February 2020
  120. CHENG BT, Silverberg JI
    Long-term and multiple hospital readmissions after discharge for Stevens-Johnson Syndrome and toxic epidermal necrolysis.
    Br J Dermatol. 2020 Feb 4. doi: 10.1111/bjd.18923.
    PubMed     Abstract available

    December 2019
  121. O'REILLY P, Kennedy C, Meskell P, Coffey A, et al
    The psychological impact of Stevens-Johnson syndrome and toxic epidermal necrolysis on patients' lives: A critically appraised topic.
    Br J Dermatol. 2019 Dec 2. doi: 10.1111/bjd.18746.
    PubMed     Abstract available

    November 2019
  122. WONG AYS, Froslev T, Forbes HJ, Kjaersgaard A, et al
    Partner bereavement and risk of psoriasis and atopic eczema: cohort studies in the United Kingdom and Denmark.
    Br J Dermatol. 2019 Nov 28. doi: 10.1111/bjd.18740.
    PubMed     Abstract available

    August 2019
  123. CHABY G, Maldini C, Haddad C, Lebrun-Vignes B, et al
    Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal necrolysis) in France during 2003-2016: a four-source capture-recapture estimate.
    Br J Dermatol. 2019 Aug 9. doi: 10.1111/bjd.18424.
    PubMed     Abstract available

    July 2019
  124. BETTUZZI T, Penso L, de Prost N, Hemery F, et al
    Trends in mortality rates for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): experience of a single center in France between 1997 and 2017.
    Br J Dermatol. 2019 Jul 19. doi: 10.1111/bjd.18360.
    PubMed     Abstract available

    June 2019
  125. MOLLANAZAR NK, Qiu CC, Aldrich JL, Tedaldi E, et al
    Use of Dupilumab in HIV-positive Patients: Report of Four Cases.
    Br J Dermatol. 2019 Jun 17. doi: 10.1111/bjd.18222.
    PubMed     Abstract available

    May 2019
  126. LEE HH, Patel KR, Singam V, Rastogi S, et al
    Associations of cutaneous and extra-cutaneous infections with Hidradenitis Suppurativa in US children and adults.
    Br J Dermatol. 2019 May 2. doi: 10.1111/bjd.18093.
    PubMed     Abstract available

    March 2019
  127. CASSIUS C, Davis CJ, Bravard P, Carre-Gislard D, et al
    Look-alike and sound-alike drugs: A potential cause of cutaneous adverse reactions to drugs.
    Br J Dermatol. 2019 Mar 3. doi: 10.1111/bjd.17842.
    PubMed     Abstract available

    February 2019
  128. NAPOLITANO M, Megna M, Fabbrocini G, Nistico SP, et al
    Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
    Br J Dermatol. 2019 Feb 15. doi: 10.1111/bjd.17779.
    PubMed     Abstract available

  129. STORAN ER, Woolf RT, Smith CH, Pink A, et al
    Clearance of molluscum contagiosum virus infection in patients with atopic eczema treated with dupilumab.
    Br J Dermatol. 2019 Feb 4. doi: 10.1111/bjd.17712.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hypersensitivity Reaction is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.